NVS News and Press, Novartis AG From 04/19/24

2024-04-19 06:13:03 ET More on Bristol-Myers Squibb, Gilead, etc. Johnson & Johnson: Buy This Bargain Before It's Gone Bristol-Myers Squibb: Market Pessimism Won't Last Forever Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript FDA approves Alvo...

2024-04-18 13:59:29 ET Summary Caribou Biosciences, Inc. is expected to produce results from phase 1 ANTLER study, using CB-010 for the treatment of 2nd-line large B-cell lymphoma patients, at medical meeting Q2 of 2024. Initial dose escalation data from the phase 1 ANTLER study i...

2024-04-18 13:15:50 ET More on TG Therapeutics TG Therapeutics: The Cloud Over Briumvi TG Therapeutics: BRIUMVI Development Could Lead To Great Results TG Therapeutics: Briumvi Growth Story Appears Intact TG Therapeutics jumps after second consecutive quarter...

2024-04-18 07:28:39 ET Summary On April 16, Johnson & Johnson released financial results for the first three months of 2024, which were within my expectations. Tecvayli sales were $133 million in the first quarter of 2024, up 111% year over year. Despite increased competit...

2024-04-17 10:24:12 ET Summary TG Therapeutics shares are down 60% from their 52-week high after rival MS therapy Ocrevus achieved non-inferiority as a subcutaneously injected therapy. Initial sales of TG Therapeutics' anti-CD20 MS treatment Briumvi were solid, generating $92 mill...

2024-04-17 09:30:00 ET Great dividend stocks don't always have particularly high yields. Still, it's nice to see a solid income stock that boasts one that's higher than average. And if this company can reward its shareholders by constantly raising its payouts -- and if it can do so for long...

2024-04-17 09:26:31 ET More on CVS Health CVS Health: Seizing Opportunity Amid Recent Declines CVS Health: Good Management Is Keeping Their Promises CVS Health: Here Comes The Floor - Inherent Undervaluation Triggers Great Upside Potential Dividend Roundup: P...

2024-04-16 14:16:55 ET Summary Just as the "Magnificent 7" stocks lead returns and headlines in US markets, an 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. Here I run a head-to-head comparison using the Magnificent 7 as a proxy for the Invesco QQQ ET...

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) PR Newswire APPLAUSE-IgAN is first and only Phase III study to demonstrate significant...

2024-04-13 10:52:04 ET More on AbbVie, Amgen, etc. AbbVie: Bulletproof Fundamentals AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% UnitedHealth Q1 2024 Earnings Preview: Headwinds Not Enough To Derail This Juggernaut GLP-1s benefit Park...